Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.
Mustafa GürbüzErman AkkuşAbdullah SakinSemiha UrvayAtike Gökçen DemiraySuleyman SahinTeoman SakalarCihan ErolMehmet Ali Nahit ŞendurAhmet Bilgehan ŞahinErdem CubukcuDeniz Can GuvenSaadettin KılıçkapYakup ErgünDoğan UncuNazım Serdar TurhalNecdet ÜskentHavva Yeşil ÇinkirAtakan DemirRamazan AcarNuri KaradurmusSema TürkerMustafa AltınbaşMert KaraoğlanFiliz Çay ŞenlerPublished in: Journal of gastrointestinal cancer (2021)
Trastuzumab maintenance ± capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer.
Keyphrases
- metastatic breast cancer
- locally advanced
- neoadjuvant chemotherapy
- epidermal growth factor receptor
- cross sectional
- phase ii study
- multiple sclerosis
- rectal cancer
- squamous cell carcinoma
- palliative care
- tyrosine kinase
- single cell
- electronic health record
- metastatic colorectal cancer
- phase iii
- big data
- randomized controlled trial
- lymph node
- open label